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In recent years, there has been a growing appreciation by regulatory authorities that
cannabis-based medicines can play a useful role in disease therapy. Although often
conflagrated by proponents of recreational use, the legislative rescheduling of
cannabis-derived compounds, such as cannabidiol (CBD), has been associated with
the steady increase in the pursuit of use of medicinal cannabis. One key driver in this
interest has been the scientific demonstration of efficacy and safety of CBD in
randomised, placebo-controlled clinical trials in children and young adults with
difficult-to-treat epilepsies, which has encouraged increasing numbers of human trials
of CBD for other indications and in other populations. The introduction of CBD as the
medicine Epidiolex in the United States (in 2018) and as Epidyolex in the European
Union (in 2019) as the first cannabis-derived therapeutic for the treatment of seizures
was underpinned by preclinical research performed at the University of Reading. This
work was awarded the British Pharmacological Society Sir James Black Award for
Contributions to Drug Discovery 2019 and is discussed in the following review article.
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1 | INITIAL INTEREST IN CANNABIS
COMPONENTS FOR TREATMENT OF
EPILEPSIES
General interest in the potential therapeutic utility of non-
tetrahydrocannabinol (THC) cannabinoids was pioneered by
researchers such as Raphael Mechoulam at the Hebrew University of
Jerusalem in Israel and Roger Pertwee, initially at Oxford University
and then at Aberdeen University. In 2007, Gary Stephens and Ben
Whalley had established an electrophysiology group at the University
of Reading within the then new School of Pharmacy; they joined with
Claire Williams from the School of Psychology and Clinical Language
Sciences to investigate the role of plant-derived cannabinoids in
different acute seizure models. Prior to joining the University of
Reading, Ben Whalley, working with Andrew Constanti and Elizabeth
Williamson at the London School of Pharmacy, had shown that
standardised cannabis extracts lacking THC could inhibit muscarinic
receptor agonist-induced epileptiform-like activity in ex vivo rat
piriform cortical brain slices (Wilkinson et al., 2003). In parallel,
Gary Stephens had an interest in the coupling of G protein-coupled
receptors (GPCRs), such as cannabinoid CB1 receptors, to downstream
signalling pathways including voltage-gated calcium channels
(Stephens, Canti, Page, & Dolphin, 1998; Stephens & Mochida, 2005;
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reviewed in Stephens, 2009). Claire Williams had complementary
expertise in animal models of disease and, working with Tim Kirkham
at Reading, had reported extensively on the effects of plant-derived
phytocannabinoids, endocannabinoids, and exogenous cannabinoids
in appetitive behavioural models. This work had demonstrated the role
of CB1 receptors in hyperphagia and highlighted the potential to
target such receptors in obesity disorders (Williams & Kirkham, 1999;
Williams, Rogers, & Kirkham, 1998; reviewed in Kirkham &
Williams, 2004).
The common research interest of the team at Reading centred
around epilepsy, a range of syndromes characterised by hyper-
excitable neural networks in the brain, which clinically manifest as sei-
zures and are associated with a clear unmet clinical need. Worldwide,
there are around 65 M people with epilepsy, making it the most prev-
alent global neurological condition; however, around one third of
patients with epilepsy do not respond to current anti-epileptic drugs
(AEDs) and therefore live with uncontrolled seizures (Janmohamed,
Brodie, & Kwan, 2019). Despite anecdotal reports of cannabis having
therapeutic benefit in epilepsy, there had been little rigorous scientific
research between 1970 and 2010 to support any clinical use, in
particular with regard to preclinical efficacy, or safety and toxicity
data. Our focus, cannabidiol (CBD), was isolated in 1963 (Mechoulam
& Shvo, 1963) and first investigated functionally in the early 1970s
(Paton & Pertwee, 1972). Amongst a few small-scale case studies, of
particular interest was a study in Brazil suggesting that plant-derived
CBD had potential utility in seizures (Cunha et al., 1980). By contrast,
some reports had implicated THC as a pro-convulsant agent
(as discussed in Rosenberg, Tsien, Whalley, & Devinsky, 2015). These
findings were further set against the desire to find agents that did not
promote the euphoria associated with recreational THC use.
The interest in use of non-psychoactive cannabinoids was
supported by the introduction of Sativex (nabiximols, a 50:50 mixture
of the two principal components of Cannabis sativa, THC and CBD) to
relieve spasticity and pain associated with multiple sclerosis, rep-
resenting the first cannabis-based medicine to be licensed in the
United Kingdom. Thus, Stephens, Whalley, and Williams began collab-
orating with the intention of testing isolated cannabinoid extracts in
seizure and epilepsy models. The makers of Sativex, GW Pharmaceuti-
cals, initially partnering with Otsuka Pharmaceuticals, Japan, provided
funding in 2007 to conduct preclinical research to assess the thera-
peutic potential of isolated phytocannabinoids in in vivo models of
chemically induced seizures and associated in vitro studies to investi-
gate modes and mechanisms of action. Individual phytocannabinoids,
including CBD, were investigated as botanical drug substances.
Initial work using the Mg2+-free and the 4-aminopyridine models
of epileptiform activity in ex vivo rat hippocampal brain slices demon-
strated clear CBD effects on local field potential burst amplitude, dura-
tion, and frequency in different cornus ammonis and dentate gyrus
regions (Jones et al., 2010). Complementary work investigated the
effects of CBD, applied via the intraperitoneal route, in a range of rat
models of acute seizure induced by chemicals including
pentylenetetrazole (PTZ) (to model generalised seizures) (Jones
et al., 2010), pilocarpine (temporal lobe seizures), and penicillin (partial
seizures) (Jones et al., 2012). Our initial in vivo work identified CBD as
a major phytocannabinoid with the greatest anticonvulsant potential
across all of the acute seizure models tested (Figure 1). It was similarly
shown that intraperitoneal CBD was anticonvulsant in rat and mouse
maximal electroshock seizure (MES) models, and in 6-Hz psychomotor
and corneal kindling models, and that intravenous CBD was also effec-
tive in reduced seizure severity in the pilocarpine model (Patra
et al., 2019; Figure 1). The latter study also showed that chronic admin-
istration of CBD oral solutions attenuated seizure burden and motor
co-morbidities in the rat reduced intensity status epilepticus-
spontaneous recurrent seizures (RISE-SRS) model of temporal lobe epi-
lepsy (TLE) (Patra et al., 2019), the RISE-SRS model being developed
between researchers at University of Reading and Gavin Woodhall's
group at Aston University (Modebadze et al., 2016). From a pharmaco-
logical viewpoint, CBD was shown to possess only low, non-relevant
binding affinity at CB1 receptors (Jones et al., 2010); this work was in
line with studies by other groups (as reviewed by Pertwee, 2008).
These data also supported earlier work in the MES model in mice by
LisaWallace and co-workers, who demonstrated that CBD had an anti-
convulsant action, independent of effects on CB1 receptors (Wallace,
Wiley, Martin, & DeLorenzo, 2001). Following the investigation of
CBD in human genetic paediatric epilepsies (described more fully
below), we extended our studies to the effects of CBD in
corresponding mouse models. In particular, we investigated models of
Dravet syndrome (DS), a genetic disease due to a voltage-gated sodium
channel (VGSC) SCN1A gene mutation. It was shown that chronic CBD
(100 mgkg−1 injected subcutaneously twice daily) treatment was able
to increase survival in Scn1a−/− mice and prevent premature mortality
F IGURE 1 CBD reduces seizure severity in different rat models
of chemically induced acute seizure. Intraperitoneal CBD
(100 mgkg−1) caused a significant reduction in seizure severity
induced by pentylenetetrazole (80 mgkg−1 i.p., n = 15; Jones
et al., 2010), penicillin 525 IU intracerebroventricular infusion
(n = 17–18; Jones et al., 2012), or pilocarpine (380 mgkg−1 i.p.,
n = 15; Jones et al., 2010). Intravenous CBD (10 mgkg−1) caused a
significant reduction in seizure severity induced by pilocarpine
(380 mgkg−1 i.v., n = 12–15; Patra et al., 2019). *P < 0.05,
nonparametric binomial test
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and improve associated co-morbidities in Scn1a+/− mice (Patra
et al., 2020). Such preclinical work provided a strong association with
the clinical data that had emerged following our initial work.
We have also investigated the effects of other
phytocannabinoids. These compounds included the THC homologue
tetrahydrocannabivarin (THCV), cannabigerol (CBG), and the CBD
homologue cannabidivarin (CBDV). We initially showed that THCV
had actions analogous to CB1 receptor antagonists on inhibitory neu-
rotransmission at interneuron-Purkinje cell synapses (Ma, Weston,
Whalley, & Stephens, 2008). THCV was also shown to act as a CB1
receptor antagonist in ligand binding and GTPγS binding assays
(Dennis, Whalley, & Stephens, 2008; Hill et al., 2010). Interestingly,
THCV reduced epileptiform activity induced by Mg2+-free media in
adult rat piriform cortical brain slices and demonstrated anticonvul-
sant effects against PTZ-induced generalised seizures in adult rats
(Hill et al., 2010). The potential clinical utility of CB1 receptor antago-
nists was however challenged by the high-profile withdrawal of the
prototypic agent rimonabant. CBG was also shown to lack anticonvul-
sant effects in the PTZ model of generalised seizures (Hill
et al., 2014). More prominently, we also demonstrated that CBDV
possessed useful anticonvulsant effects in in vitro and in vivo seizure
models (Amada, Yamasaki, Williams, & Whalley, 2013; Hill, Williams,
Whalley, & Stephens, 2012). The former study further detailed the
suppressive effects of CBDV on expression of specific epilepsy-
related genes. We further demonstrated that the anticonvulsant
effects of CBDV-rich cannabis extracts occurred independently of
actions at CB1 receptors (Hill et al., 2013). There are ongoing investi-
gations into the potential clinical utility of CBDV in epilepsy; however,
overall preclinical data in in vivo seizure models generated at the
University of Reading strongly suggested CBD as a prominent canna-
binoid which had clear potential to address the unmet clinical need
associated with different forms of epilepsy.
2 | THE HUMAN EXPERIENCE
In parallel with efforts within the scientific research community, fami-
lies of children with difficult-to-treat childhood epilepsies were begin-
ning to connect with cannabis growers who were developing
previously ‘forgotten’ high-CBD cannabis strains. The realisation that
such strains may possess anti-seizure effects began to emerge via
social and mainstream media. A notable example was the story of
Charlotte Figi, which was captured in a memorable 2013 CNN docu-
mentary. At that time, Charlotte was a 5-year-old American girl who
suffered dozens of seizures a day due to intractable DS, a disease
associated with average life expectancy of just 8 years. Local pro-
ducers of cannabis oil in Colorado developed a specialised high
CBD/low THC product, later dubbed “Charlotte's Web,” which was
able to cause a remarkable reduction in Charlotte's seizure rate (Maa
& Figi, 2014). Against a backdrop of Charlotte being a twin to a
healthy sister, together with her father being in the US military, the
human-interest documentary helped propel potential use of ‘medical
marijuana’ into the public's consciousness. Other growers began to
develop high CBD/low THC strains, and several families began to seek
access to such strains, some via knowledge of the publications from
University of Reading. In particular, the mother of Sam Vogelstein
(a child with intractable childhood epilepsy who became Epidiolex
patient #1) contacted GW Pharmaceuticals, citing the work of Jones
et al. (2010), to request access to CBD. The treatment reportedly had
significant efficacy—after 3 days of treatment, Sam was down from
dozens of seizures per day to around one seizure per day. This led to
the family being permitted by the Food and Drug Administration
(FDA) to use CBD under a compassionate use program in California;
the success of this program led to the pursuit of wider trials across
more epilepsy centres. Thus, one of the foremost US epilepsy clini-
cians, Orrin Devinsky, Professor of Neurology at NYU Langone School
of Medicine, oversaw moves towards the first randomised, controlled
human clinical trials of CBD in patients with DS and another devastat-
ing paediatric epilepsy, Lennox–Gastaut syndrome (LGS). DS and LGS
represent two of the most difficult to treat genetic childhood epilepsy
syndromes; as patients with these syndromes have severely reduced
lifespans and are commonly resistant to traditional AEDs, they repre-
sented a significant unmet need for new therapeutic options. These
trials were further facilitated by the FDA decision in 2013 to grant
CBD an Orphan Drug designation (i.e., special status to a drug with
clear potential treat a rare disease, as defined in the United States as a
condition that affects fewer than 200,000 people). Although classified
as “rare” orphan diseases, figures from National Organization for Rare
Diseases can be used to estimate that there are around
45,000–70,000 patients with DS and LGS in the United States. Such
people with epilepsy present with multiple seizure types, commonly
resistant to traditional AEDs, as well as developmental delay and
numerous co-morbidities.
From 2014, open-label trials in patients with treatment-resistant
epilepsy, including DS and LGS, were initiated. Such trials first
reported an encouraging 36.5% median reduction in monthly motor
seizures (Devinsky et al., 2016). Following successful Phase 2 trials
(Devinsky et al., 2017; Devinsky, Patel, Thiele, & GWPCARE1 Part A
Study Group, 2018), the first pivotal positive Phase 3 study results
for CBD in the treatment of DS and LGS were announced. Each of
these clinical studies recruited patients typically with a history of
using at least two previous AEDs and displaying at least two uncon-
trolled seizures weekly during a 4-week pretreatment baseline.
Across the studies, treatment groups displayed a significant 20 per-
centage point decrease in seizures compared to placebo. Based on
these positive human trials, the FDA approved Epidiolex as the first
prescription plant extract cannabinoid medicine in the United States
and as the first in a new class of anti-epileptic medications for the
treatment of pharmacoresistant seizures in children and young adults
with DS and LGS. Overall, the GWPCARE1 and GWPCARE2 trials
demonstrated that an oral suspension of CBD at 10 or
20 mgkg−1day−1 two times a day had an acceptable safety profile
and that individuals with treatment-resistant DS achieved a
sustained, clinically meaningful reduction in monthly convulsive sei-
zures compared with a placebo (Devinsky et al., 2017; Devinsky,
Patel, Thiele, et al., 2018; Miller et al., 2020). Similarly, Phase 3 trials
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for oral CBD in LGS (GWPCARE3 and GWPCARE 4) were also posi-
tive (Devinsky, Patel, Cross, et al., 2018; Thiele et al., 2018). Thus,
four major trials were carried out, recruiting a total of 550 (DS, 154;
LGS, 396) patients who had previously been unable to control their
seizures despite AED polytherapy (see Morano et al., 2020). An
open-label extension trial, GWPCARE5, with 630 subjects (DS, 264;
LGS, 366) further supported oral CBD safety and persistence efficacy
in DS and LGS patients (Devinsky et al., 2019; Thiele, Bebin,
et al., 2019). Prior to Epidiolex being available for prescription, it has
been estimated that over 2,000 patients had already been treated
through GW's compassionate use program and open-label extension.
Epidiolex became available for prescription in the United States in
November 2018. The Drug Enforcement Agency reclassified CBD
(containing no more than 0.1% [w/w] residual THC) to Schedule V,
indicating proven medical use and low potential for abuse. Similar
European Medicine Authority approval for CBD followed in 2019,
under the brand name Epidyolex. In the United Kingdom, the medi-
cine became fully available on the NHS in January 2020. Drug sched-
uling of cannabis in the United Kingdom has been under regular
review, and in November 2018, “cannabis-based products for medici-
nal use (CBPMs)” were reclassified from Schedule 1 controlled drugs
(compounds of no medical value) into Schedule 2 of the Misuse of
Drugs Regulations 2001. Most recently, Epidyolex was reclassified as
a Schedule 5 drug in the United Kingdom.
During approval, FDA Commissioner Scott Gottlieb stated in a
press release: “This approval serves as a reminder that advancing
sound development programs that properly evaluate active ingredi-
ents contained in marijuana can lead to important medical therapies.
And, the FDA is committed to this kind of careful scientific research
and drug development.”
3 | CBD MECHANISM OF ACTION
A definitive pharmacological target for CBD in epilepsy (and else-
where) remains elusive, with various reports of pharmacologically rele-
vant affinity at several molecular targets (Gray & Whalley, 2020;
Senn, Cannazza, & Biagini, 2020). The best recognised targets include
transient receptor potential vanilloid channels and GPCR 18 (GPR18)
and GPR55 receptors (Alexander et al., 2019). Work at the University
of Reading has contributed to descriptions of CBD activation, and
subsequent desensitisation, of transient receptor potential vanilloid 1
(TRPV1), TRPV2, and transient receptor potential ankyrin 1 (TRPA1)
(Iannotti et al., 2014). We have also shown that CBD blocks the
activation of GPR55 receptors by the endogenous lipid agonist
lysophosphatidylinositol in ex vivo brain slices taken from rats dis-
playing spontaneous epileptiform activity (Rosenberg et al., 2018).
Pharmacological blockage/antagonism and/or transgenic technol-
ogy is good evidence to define mechanism of action. One recent study
demonstrates that CBD's anticonvulsant properties were attenuated
in TRPV1 knockout mice (Gray, Stott, Jones, Di Marzo, &
Whalley, 2020). CBD also acts as allosteric modulator of 5HT1A; how-
ever, one specific study has ruled out 5HT1A as a CBD target in
seizure control (Pelz, Schoolcraft, Larson, Spring, & Lopez, 2017). CBD
was also shown to act as a blocker of VGSCs (Hill et al., 2014), which
represents a potential mode of anticonvulsive action in epilepsy.
However, another phytocannabinoid, CBG, was shown to share block-
ade of VGSCs but, unlike CBD, had no clear effect on PTZ-induced
seizures in rats (Hill et al., 2014). CBD has also been shown to retain
anti-seizure effects and improve social deficits and survival in a mouse
model of DS (Kaplan, Stella, Catterall, & Westenbroek, 2017; Patra
et al., 2020), itself a syndrome associated with a loss-of-function
mutation to NaV1.1 VGSCs. Moreover, nanomolar CBD was effective
in regulating neuronal excitability without effects on VGSCs in a
human-induced pluripotent stem cell-based model of DS (Sun &
Dolmetsch, 2018). Such data suggest that VGSCs were not the pri-
mary CBD target in epilepsy; these findings are significant as current
AEDs which act as VGSC blockers are known to exacerbate DS.
As described above, CBD has only very low affinity at CB1 recep-
tors; correspondingly, CBD lacks any appreciably coupling to G pro-
tein turnover (Jones et al., 2010). There are however reports that
CBD can act as a negative allosteric modulator at CB1 receptors
(Laprairie, Bagher, Kelly, & Denovan-Wright, 2015; Straiker,
Dvorakova, Zimmowitch, & Mackie, 2018) and also as a partial agonist
at CB2 receptors (Tham et al., 2019). Of further mechanistic interest is
our recent study which was consistent with CBD ameliorating the
pro-convulsant effect of long-term THC treatment in rats (Whalley
et al., 2018). In this study, we also described a potential mechanism
whereby CBD reduced THC-mediated CB1 receptor activation in a
species-specific way (Figure 2); such CBD actions may reflect a func-
tional reduction in seizures, for example, via negative allosteric modu-
lation of CB1 receptors.
Several other potential molecular targets of CBD, including classi-
cal receptors, ion channels, transporters, and enzymes, have been pro-
posed (reviewed by us in Hill et al., 2012; Ibeas Bih et al., 2015;
Turner, Williams, Iversen, & Whalley, 2017). Most prominent amongst
these are alternative receptor targets including 5HT1A, adenosine
receptor subtypes, and PPARγ nuclear receptors; additional ion
channel targets including CaV3 voltage-gated calcium channels and
mitochondrial voltage-dependent anion-selective channel protein
1 (VDAC1); adenosine transporters; and, potentially, enzymes
involved in the endocannabinoid system, such as fatty acid amide
hydrolase. One common CBD effect may be the modulation of down-
stream levels of calcium as a second messenger (see Ibeas Bih
et al., 2015). In this regard, CBD has been proposed to regulate mito-
chondrial control (potentially via VDAC1) of intracellular calcium levels
in hippocampal neurons and to restore homeostasis in pathological
situations (Ryan, Drysdale, Lafourcade, Pertwee, & Platt, 2009); such
function may contribute to CBD effects in epilepsy. More recently,
we and co-workers have shown that CBD can act on a glycine cleav-
age system component to inhibit synthesis of the essential amino acid
methionine, including in heterozygous Scn1a+/− mice in the DS model
(Perry et al., 2020). This work introduces one-carbon signalling as a
further potential target for CBD action.
A potential confounder in some studies is the use of high
( >10 μM) CBD concentrations. As discussed by us previously, the
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lipophilic nature of CBD means that results based on higher micromo-
lar concentrations of CBD are likely influenced by insertion of CBD
into the plasma membrane (Ibeas Bih et al., 2015). In practice, the
poor bioavailability of CBD in vivo (see below) may limit these effects.
However, the general lipophilic profile of cannabinoids, including
CBD, also means that they have potential to accumulate in fatty tissue
and be released over time. In general, more credence is typically
placed on CBD effects that occur at low/sub-micromolar concentra-
tions. Overall, CBD may exhibit a relevant “polypharmacology” profile;
there are also consistent reports of anti-oxidant and anti-
inflammatory properties of CBD which have potential to contribute to
anti-epileptic (and other) effects.
Finally here, the lack of a well-defined molecular target can lead
to speculation about the potential role of metabolites. In humans,
CBD is metabolised mainly into 7-OH-CBD and the major 7-COOH-
CBD metabolite. However, work on effects of CBD metabolites is, as
yet, still in its infancy.
4 | CLINICAL/FUTURE PERSPECTIVES
Over the last few years, there has been an explosion in interest in the
use of CBD-containing foods and supplements, supported by wide-
spread availability of numerous different CBD preparations on the
High Street and of further unregulated access via the internet. There
have been recent warnings about levels of such consumption from the
UK Food Standards Agency and efforts to curtail many
unsubstantiated claims of therapeutic benefit. The latter will, of
course, require controlled human trials which investigate appropriate
formulations of standardised product, delivered at an efficacious dose.
The original case of Charlotte Figi described above has several recent
parallels in the United Kingdom. The publicity around cases of uncon-
trolled childhood epilepsies, such as those of Billy Caldwell and Alfie
Dingley, were key in the reclassification and increased availability of
CBPMs, including those with a CBD component. These moves were
no doubt also fuelled by the approval of Epidiolex as a scientifically
tested medicine.
From a clinical viewpoint, there are challenges to effective deliv-
ery of CBD. Animal studies suggest that CBD oral bioavailability is
low (<20%) (Mechoulam, Parker, & Gallily, 2002), with CBD being
subject to extensive first-pass metabolism (Huestis, 2007); however,
wide-ranging human data for CBD bioavailability are currently
lacking (Millar et al., 2019). CBD is also associated with low water
solubility and variability in pharmacokinetic profiles (Millar, Maguire,
Yates, & O'Sullivan, 2020). Therefore, further work is needed to
establish therapeutic dosing and most effective route of administra-
tion. Clinically, Epidiolex is given as an oral solution; in addition, the
CBD-containing medicine Sativex is administered sublingually to
avoid first-pass metabolism. CBD bioavailability may be improved by
intranasal delivery (e.g., of vaporised drug) or even by transdermal
delivery (Paudel, Hammell, Agu, Valiveti, & Stinchcomb, 2010). How-
ever, of interest for anticonvulsant effects is that CNS levels of CBD
were found to be higher via the oral, compared to the inhaled,
route; moreover, such exposure correlated with increased behav-
ioural effects (Hložek et al., 2017).
There is a well-described “entourage effect,” originally posited for
the endocannabinoid system by Ben-Shabat et al. (1998), whereby
cannabinoid effects are synergically increased by associated compo-
nents. Such effects have also been ascribed to CBD and to Epidiolex,
which represents a 98% CBD plant extract; however, future con-
trolled human trials will be required to more fully define this effect.
Some evidence in support of CBD synergism comes from a recent
meta-analysis of observational clinical studies that concluded patients
required 4-fold less CBD dose in enriched plant extracts versus puri-
fied drug and that adverse effects were also reduced in extracts
(Pamplona, da Silva, & Coan, 2018). An additional challenge is to
define the nature and contribution of the highly numerous additional
components in cannabis.
Epilepsy is a condition prone to a “honeymoon” effect, that is, a
reduction of initial drug efficacy with prolonged use, often associated
with development of tolerance to AEDs (Avanzini, 2006; Dale
et al., 2019). It remains unclear if people with epilepsy will develop
F IGURE 2 CBD affects THC-stimulated 35S-GTPγS turnover in
cerebellar tissue in a species-specific manner. CBD (applied at a THC:
CBD 1.08:1 ratio) attenuated THC-stimulated G protein turnover in
rat and chicken, but not human, tissue. Note that in human tissue,
THC-stimulated G protein turnover was of generally lower magnitude.
*P < 0.05, ANOVA followed by a Tukey's post hoc test on raw data
from three separate experiments in triplicate, preparations from
multiple brains (data derived from Whalley et al., 2018)
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similar tolerance to CBD. At present, there is no published evidence
for CBD tolerance in other conditions; however, a recent open-label
study reported that around one third of paediatric and adults with dif-
ferent treatment resistance epilepsies showed some tolerance to
CBD-enriched oil in terms of reduced control of mean monthly seizure
frequency (although concomitant medication was maintained) (Uliel-
Sibony, Hausman-Kedem, Fattal-Valevski, & Kramer, 2020). Follow-up
studies to further investigate CBD tolerance in epilepsy, and its rele-
vance in comparison to AEDs, are thus warranted.
Epidiolex may be given as a monotherapy in the United States in
uncontrolled DS and LGS and Epidyolex as an adjunct to standard
anti-epileptic therapies in the European Union. CBD is generally con-
sidered a safe drug (Taylor, Gidal, Blakey, Tayo, & Morrison, 2018), in
particular, in comparison to standard AEDs (Bergamaschi, Queiroz,
Zuardi, & Crippa, 2011; Iffland & Grotenhermen, 2017). Original
studies reported that CBD caused some adverse effects, including
tiredness, diarrhoea, and changes of appetite/weight (Huestis
et al., 2019); however, many such adverse effects occur at doses
higher than those used for seizure control. A major CBD effect is
inhibition of hepatic drug metabolism leading to recognised, signifi-
cant increases in the levels of several co-administered AEDs (Gaston,
Bebin, Cutter, Liu, & Szaflarski, 2017). A common standard AED used
in conjunction with Epidiolex is clobazam. One report (in a preclinical
model) has proposed that an interaction between CBD and clobazam
may underlie improved anti-epileptic profiles (Anderson et al., 2019),
potentially via CBD inhibition of CYP2C19, which metabolises
clobazam. However, recent open-label studies have shown that such
interactions appear to have no effect on seizure frequency and sever-
ity outcomes in the patient population (Gaston et al., 2019; Savage
et al., 2019). Isobolographic studies (which are gold standard for
pharmacological interactions) for CBD (and 7-OH-CBD) and clobazam
(and the major metabolite N-desmethylclobazam) indicated a
synergistic action in the MES mouse model of acute generalised
seizures that occurred independently of pharmacokinetic interaction
(Rana, 2019). A recent meta-analysis further suggests that CBD has
anti-seizure efficacy independent of clobazam administration
(Lattanzi et al., 2020).
With the recent approval of Epidiolex, several other disease
states are the subject of intense investigation with regard to CBD use,
with many now progressing to human trials. Recent reviews have out-
lined clinical work on CBD in, amongst others, Parkinson's disease and
psychosis, society anxiety disorder, Rett syndrome, schizophrenia,
cognitive dysfunction, and ulcerative colitis and Crohn's disease, as
well as the potential for CBD to counteract recreational use of canna-
bis and dependence on opioids (Millar et al., 2019; Pauli, Conroy, Van
Den Heuval, & Park, 2020). In particular, positive results from Phase
III trials showing that CBD reduced seizures associated with Tuberous
Sclerosis Complex (TSC) were reported in the GWPCARE6 study
(Thiele, Marsh, et al., 2019); this work was also supported by our
mechanistic work on CBD effects in a zebrafish model of TSC (Serra
et al., 2019). CBD is also being widely investigated in different forms
of cancer (Hinz & Ramer, 2019). This activity strongly suggests that
CBD therapeutic use will likely soon extend to other conditions.
Thus, preclinical developmental work on CBD at the University
of Reading leading to the introduction of Epidiolex for the treat-
ment of severe childhood epilepsies has been recognised by the
British Pharmacological Society, which has awarded Stephens,
Whalley, and Williams the 2019 Sir James Black Award for
Contributions to Drug Discovery. Much of this initial and ongoing
work has been published in the British Journal of Pharmacology,
including in different themed issues on cannabinoids, and has been
presented at European Workshops on Cannabinoid Research
organised by the BPS and several annual BPS Pharmacology meet-
ings. The commitment of the BPS to this area of preclinical work
has helped push CBD to the clinic for paediatric epilepsies; it is
highly likely that additional areas of therapeutic utility will arise in
the next few years for CBD and perhaps other plant-derived
cannabinoids.
4.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, and
are permanently archived in the Concise Guide to PHARMACOLOGY
2019/20 (Alexander et al., 2019).
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